If the subject were to undergo unexpected outcomes and no longer wants to take part in the trial, it is up to their discretion to continue or to end their treatment. Informed consent includes consent throughout the entirety of the trial. If at any point the consent is to be withdrawn, the company must respect that. In the event of unexpected or harmful results, the company should evaluate their process and pull back the specific drug or treatment they are testing and refine it and undergo preclinical testing again before bringing it to clinical trials. The original treatment should not be approved.